Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361960900> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4361960900 abstract "<div>Abstract<p><b>Purpose:</b> VEGF, EGF, and TGF-α are expressed in hepatocellular carcinomas (HCC) and play a role in its growth. Vandetanib, a multikinase inhibitor, suppresses the phosphorylation of VEGF receptor 2 (VEGFR-2) and EGF receptor (EGFR). The aim of this study was to clarify the antitumor effect of vandetanib in mouse HCCs.</p><p><b>Experimental Design:</b> We evaluated the effects of vandetanib on proliferation of human umbilical vein endothelial cells (HUVEC) and three hepatoma cell lines, as well as the phosphorylation of VEGFR-2 and EGFR in these cells. Mice were implanted with hepatoma cells subcutaneously or orthotopically in the liver and treated with 50 or 75 mg/kg vandetanib. We analyzed the effects of treatment on tumor cell proliferation and apoptosis, vessel density, phosphorylation of VEGFR-2 and EGFR, and production of VEGF, TGF-α, and EGF in tumor tissues. Adverse events on vandetanib administration were also investigated.</p><p><b>Results:</b> Vandetanib suppressed phosphorylation of VEGFR-2 in HUVECs and EGFR in hepatoma cells and inhibited cell proliferation. In tumor-bearing mice, vandetanib suppressed phosphorylation of VEGFR-2 and EGFR in tumor tissues, significantly reduced tumor vessel density, enhanced tumor cell apoptosis, suppressed tumor growth, improved survival, reduced number of intrahepatic metastases, and upregulated VEGF, TGF-α, and EGF in tumor tissues. Treatment with vandetanib was not associated with serious adverse events, including alanine aminotransferase abnormality, bone marrow suppression, or body weight loss.</p><p><b>Conclusions:</b> The antitumor effects of vandetanib in mice suggest that it is a potentially suitable and safe chemotherapeutic agent for HCCs. <i>Clin Cancer Res; 18(14); 3924–33. ©2012 AACR</i>.</p></div>" @default.
- W4361960900 created "2023-04-05" @default.
- W4361960900 creator A5012513340 @default.
- W4361960900 creator A5013194037 @default.
- W4361960900 creator A5021562894 @default.
- W4361960900 creator A5021957719 @default.
- W4361960900 creator A5032328519 @default.
- W4361960900 creator A5047725445 @default.
- W4361960900 creator A5049570653 @default.
- W4361960900 creator A5084794851 @default.
- W4361960900 creator A5084839932 @default.
- W4361960900 creator A5088773176 @default.
- W4361960900 creator A5089378983 @default.
- W4361960900 date "2023-03-31" @default.
- W4361960900 modified "2023-10-14" @default.
- W4361960900 title "Data from Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice" @default.
- W4361960900 doi "https://doi.org/10.1158/1078-0432.c.6520143" @default.
- W4361960900 hasPublicationYear "2023" @default.
- W4361960900 type Work @default.
- W4361960900 citedByCount "0" @default.
- W4361960900 crossrefType "posted-content" @default.
- W4361960900 hasAuthorship W4361960900A5012513340 @default.
- W4361960900 hasAuthorship W4361960900A5013194037 @default.
- W4361960900 hasAuthorship W4361960900A5021562894 @default.
- W4361960900 hasAuthorship W4361960900A5021957719 @default.
- W4361960900 hasAuthorship W4361960900A5032328519 @default.
- W4361960900 hasAuthorship W4361960900A5047725445 @default.
- W4361960900 hasAuthorship W4361960900A5049570653 @default.
- W4361960900 hasAuthorship W4361960900A5084794851 @default.
- W4361960900 hasAuthorship W4361960900A5084839932 @default.
- W4361960900 hasAuthorship W4361960900A5088773176 @default.
- W4361960900 hasAuthorship W4361960900A5089378983 @default.
- W4361960900 hasBestOaLocation W43619609002 @default.
- W4361960900 hasConcept C11960822 @default.
- W4361960900 hasConcept C126322002 @default.
- W4361960900 hasConcept C134018914 @default.
- W4361960900 hasConcept C170493617 @default.
- W4361960900 hasConcept C185592680 @default.
- W4361960900 hasConcept C2779438470 @default.
- W4361960900 hasConcept C2780333294 @default.
- W4361960900 hasConcept C42362537 @default.
- W4361960900 hasConcept C502942594 @default.
- W4361960900 hasConcept C55493867 @default.
- W4361960900 hasConcept C62112901 @default.
- W4361960900 hasConcept C71924100 @default.
- W4361960900 hasConceptScore W4361960900C11960822 @default.
- W4361960900 hasConceptScore W4361960900C126322002 @default.
- W4361960900 hasConceptScore W4361960900C134018914 @default.
- W4361960900 hasConceptScore W4361960900C170493617 @default.
- W4361960900 hasConceptScore W4361960900C185592680 @default.
- W4361960900 hasConceptScore W4361960900C2779438470 @default.
- W4361960900 hasConceptScore W4361960900C2780333294 @default.
- W4361960900 hasConceptScore W4361960900C42362537 @default.
- W4361960900 hasConceptScore W4361960900C502942594 @default.
- W4361960900 hasConceptScore W4361960900C55493867 @default.
- W4361960900 hasConceptScore W4361960900C62112901 @default.
- W4361960900 hasConceptScore W4361960900C71924100 @default.
- W4361960900 hasLocation W43619609001 @default.
- W4361960900 hasLocation W43619609002 @default.
- W4361960900 hasOpenAccess W4361960900 @default.
- W4361960900 hasPrimaryLocation W43619609001 @default.
- W4361960900 hasRelatedWork W1963919935 @default.
- W4361960900 hasRelatedWork W1979660518 @default.
- W4361960900 hasRelatedWork W2018368842 @default.
- W4361960900 hasRelatedWork W2033472167 @default.
- W4361960900 hasRelatedWork W2034583712 @default.
- W4361960900 hasRelatedWork W2063619316 @default.
- W4361960900 hasRelatedWork W2074821979 @default.
- W4361960900 hasRelatedWork W2169225653 @default.
- W4361960900 hasRelatedWork W2414846389 @default.
- W4361960900 hasRelatedWork W2748952813 @default.
- W4361960900 isParatext "false" @default.
- W4361960900 isRetracted "false" @default.
- W4361960900 workType "article" @default.